Clinical Trials Browser

Phase 2 × Interventional × olverembatinib × Clear all

NCT07178912 2026-03-09

Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)

Phase 2 Not yet recruiting

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06817720 2026-01-14

Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Phase 2 Recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04126681 2025-03-03

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

Phase 2 Completed

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT06754267 2024-12-31

Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03883087 2023-04-03

A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation

Phase 2 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

NCT03883100 2023-04-03

A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation

Phase 2 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Accelerated Phase

NCT05521204 2022-08-30

Olverembatinib for FGFR1-rearranged Neoplasms

Phase 2 Recruiting

Myeloproliferative Disorders